Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Añadir filtros








Intervalo de año
1.
Indian J Physiol Pharmacol ; 2001 Jan; 45(1): 22-36
Artículo en Inglés | IMSEAR | ID: sea-107141

RESUMEN

Insulin resistance has emerged out as a concept linking diabetes mellitus and hypertension. Clinically it is characterized by hyperinsulinemia, hypertension, central obesity, abnormal lipid profile and cardiovascular complications. Insulin resistance is often associated with presence of anti-insulin antibodies and absent or dysfunctional insulin receptors. At molecular level insulin resistance appears to occur at the level of G-protein, kinase activation, glucose carriers (GLUT) and gene expression. Although with advent or research, the molecular mechanisms of insulin resistance are becoming more clear and there is development of new therapeutic agents like insulin sensitizers (thizolidinediones), in clinical practice, as of today, a patient with insulin resistance is looked upon as hypertensive or having diabetes mellitus. Accordingly he is taking either antihypertensives or antidiabetic drugs or both. It is thus essential to look into effects of these agents on insulin sensitivity. In recent years some scattered studies have been conducted to evaluate the effect of various antihypertensives and antidiabetics on insulin sensitivity. An antihypertensive or antidiabetic drug should directly benefit the cardiovascular risk profile of these patients. Although various newer approaches are explored to have a therapeutic benefit in insulin resistance, it is still a long way in the research, when a suitable pharmacological agent with least untoward effects will be available for the treatment of insulin residence.


Asunto(s)
Fosfatidilinositol 3-Quinasa/metabolismo , Animales , Inhibidores Enzimáticos/uso terapéutico , Proteínas de Unión al GTP/metabolismo , Insuficiencia Cardíaca/etiología , Humanos , Hiperglucemia/complicaciones , Hipertensión/etiología , Hipoglucemiantes/uso terapéutico , Resistencia a la Insulina/fisiología , Proteínas de Transporte de Monosacáridos/metabolismo , Fosfotransferasas/metabolismo , Transducción de Señal/fisiología
2.
Indian J Physiol Pharmacol ; 1999 Apr; 43(2): 160-4
Artículo en Inglés | IMSEAR | ID: sea-107047

RESUMEN

Erectile dysfunction is a common and multi-factorial disease that strongly impairs the quality of life in men. During the past decade, many new therapeutic strategies have become available. But the need for oral treatment was strongly felt. This need appears to have been fulfilled with the introduction of sildenafil. The drug acts by enhancing smooth muscle relaxant effect of nitric oxide. A number of clinical studies have now proved its safety and efficacy. The drug has shaken social life all over the world and to accept this "magic pill" or not remains the question of individual choice.


Asunto(s)
Ensayos Clínicos como Asunto , Interacciones Farmacológicas , Disfunción Eréctil/tratamiento farmacológico , Humanos , Masculino , Óxido Nítrico/metabolismo , Inhibidores de Fosfodiesterasa/farmacocinética , Piperazinas/efectos adversos , Purinas , Sulfonas
3.
Indian J Exp Biol ; 1998 Dec; 36(12): 1273-5
Artículo en Inglés | IMSEAR | ID: sea-63016

RESUMEN

Cataleptic effect of pentazocine in mice was affected by pretreatment with dexfenfluramine, fluoxetine, buspirone, p-chlorophenylalanine, cyproheptadine, mianserin, cisapride, ondansetron, pindolol and propranolol. The results suggest that drugs which influence the activity of central serotonergic systems do modulate pentazocine-induced catalepsy in mice.


Asunto(s)
Animales , Catalepsia/inducido químicamente , Interacciones Farmacológicas , Masculino , Ratones , Pentazocina/toxicidad , Serotonina/metabolismo , Serotoninérgicos/farmacología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA